Haematological Abnormalities in Liver Disease

Textbook of Hepatology: From Basic Science to Clinical Practice, Third Edition

Volumn , Issue , 2008, Pages 1767-1779

  Senzolo, Marco ^a   Burroughs, Andrew K ^b,c  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Erythropoiesis; Haematological abnormalities; Hypersplenism; Major site haematopoiesis; Megakaryopoiesis

Indexed keywords

EID: 84889393711     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470691861.ch21c     Document Type: Chapter

References (203)

1. Ackerman GA, Grasso JA, Knouff RA (1961) Erythropoiesis in the mammalian embryonic liver as revealed by electron microscopy. Lab Invest 10, 787-796.
2. Fried W (1972) The liver as a source of extrarenal erythropoietin production. Blood 40, 671-677.
3. Jelkmann W (1992) Erythropoietin: structure, control of production, and function. Physiol Rev 72, 449-489.
4. McDonald TP (1988) Thrombopoietin: its biology, purification, and characterization. Exp Hematol 16, 201-205.
5. Jelkmann W (2001) The role of the liver in the production of thrombopoietin compared with erythropoietin. Eur J Gastroenterol Hepatol 13, 791-801.
6. Radovic M, Jelkmann W, Djukanovic L et al. (1999) Serum erythropoietin and interleukin-6 levels in hemodialysis patients with hepatitis virus infection. J Interferon Cytokine Res 19, 369-373.
7. Kew MC, Fisher JW (1986) Serum erythropoietin concentrations in patients with hepatocellular carcinoma. Cancer 58, 2485-2488.
8. Jandl JH (1955) The anemia of liver disease: observations on its mechanism. J Clin Invest 34, 390-404.
9. Kimber C, Deller DJ, Ibbotson RN et al. (1965) The mechanism of anaemia in chronic liver disease. Q J Med 34, 33-64.
10. Phillips DL, Keeffe EB (1987) Hematological manifestations of gastrointestinal diseases. Hematol/Oncol Clin North Am 1, 207-228.
11. Sheehy TW, Berman A (1960) The anemia of cirrhosis. J Lab Clin Med 56, 72-82.
12. Mutchnick MG, Lerner E, Conn HO (1980) Effect of portacaval anastomosis on hypersplenism. Dig Dis Sci 25, 929-938.
13. Siciliano M, Tomasello D, Milani A et al. (1995) Reduced serum levels of immunoreactive erythropoietin in patients with cirrhosis and chronic anemia. Hepatology 22, 1132-1135.
14. Jensen JD, Jensen LW, Madsen JK et al. (1995) The metabolism of erythropoietin in liver cirrhosis patients compared with healthy volunteers. Eur J Haematol 54, 111-116.
15. Kajikawa M, Nonami T, Kurokawa T et al. (1993) Recombinant human erythropoietin and hypophosphatemia in patients with cirrhosis. Lancet 341, 503-504.
16. Pirisi M, Fabris C, Soardo G et al. (1994) Thrombocytopenia of chronic liver disease corrected by erythropoietin treatment. J Hepatol 21, 376-380.
17. Dooley J (2002) The haematology of liver disease. In: Sherlock S, Dooley J (eds) Diseases of the Liver and Biliary System. Oxford: Blackwell Publishing, pp. 47-64.
18. Berman L, Axelrod AR, Horan TN et al. (2005) The blood and bone marrow in patients with cirrhosis of the liver. Blood 4, 511-529.
19. Weiss G, Goodnough LT (2005) Anemia of chronic disease. N Engl J Med 352, 1011-1023.
20. Young NS (1990) Flaviviruses and bone marrow failure. JAMA 263, 3065-3068.
21. Zeldis JB, Mugishima H, Steinberg HN et al. (1986) In vitro hepatitis B virus infection of human bone marrow cells. J Clin Invest 78, 411-417.
22. Peck-Radosavljevic M (2000) Thrombocytopenia in liver disease. Can J Gastroenterol 14(Suppl. D), 60D-6D.
23. Peck-Radosavljevic M (2001) Hypersplenism. Eur J Gastroenterol Hepatol 13, 317-323.
24. Friedman LS (1999) The risk of surgery in patients with liver disease. Hepatology 29, 1617-1623.
25. Straus DJ (1973) Hematologic aspects of alcoholism. Semin Hematol 10, 183-194.
26. Bessis M, Weed RI, Le Pond PF (1973) Red Cell Shape: Physiology, Pathology, Ultrastructure. New York: Springer-Verlag.
27. Cooper RA, Arner EC, Wiley JS et al. (1975) Modification of red cell membrane structure by cholesterol-rich lipid dispersions. A model for the primary spur cell defect. J Clin Invest 55, 115-126.
28. Cooper RA (1980) Hemolytic syndromes and red cell membrane abnormalities in liver disease. Semin Hematol 17, 103-112.
29. Grahn EP, Dietz AA, Stefani SS et al. (1968) Burr cells, hemolytic anemia and cirrhosis. Am J Med 45, 78-87.
30. Owen JS, Brown DJ, Harry DS et al. (1985) Erythrocyte echinocytosis in liver disease. Role of abnormal plasma high density lipoproteins. J Clin Invest 76, 2275-2285.
31. Gisselbrecht C, Metreau JM, Dhumeaux D et al. (1977) [Acanthocytosis in cirrhosis. Report of four cases and review of the literature (author's transl.)]. Gastroenterol Clin Biol 1, 621-628.
32. Chanarin I, Hutchinson M, McLean A et al. (1966) Hepatic folate in man. Br Med J 5484, 396-399.
33. Lindenbaum J, Lieber CS (1975) Effects of chronic ethanol administration on intestinal absorption in man in the absence of nutritional deficiency. Ann NY Acad Sci 252, 228-234.
34. Grasbeck R, Nyberg W, Reizenstein P (1958) Biliary and fecal vit. B12 excretion in man: an isotope study. Proc Soc Exp Biol Med 97, 780-784.
35. Jones PN, Mills EH, Capps RB (1957) The effect of liver disease on serum vitamin B12 concentrations. J Lab Clin Med 49, 910-922.
36. Corrocher R, Bambara LM, Pachor ML et al. (1980) Different binding proteins for folic acid in serum of patients with acute hepatitis. Acta Haematol 64, 281-284.
37. Danford DE, Munro HM (1982) The liver in relation to the B vitamins. In: Arias L, Popper H, Schachter D et al. (eds) The Liver: Biology and Pathophysiology. New York: Raven Press, pp. 367-384.
38. Lambert D, Benhayoun S, Adjalla C et al. (1997) Alcoholic cirrhosis and cobalamin metabolism. Digestion 58, 64-71.
39. Geissbuhler P, Mermillod B, Rapin CH (2000) Elevated serum vitamin B12 levels associated with CRP as a predictive factor of mortality in palliative care cancer patients: a prospective study over five years. J Pain Symptom Manage 20, 93-103.
40. Boisson F, Fremont S, Migeon C et al. (1999) Human haptocorrin in hepatocellular carcinoma. Cancer Detect Prev 23, 89-96.
41. Bentley DP (1982) Anaemia and chronic disease. Clin Haematol 11, 465-479.
42. Means RT Jr, Krantz SB (1992) Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 80, 1639-1647.
43. Chapman RW, Morgan MY, Boss AM et al. (1983) Acute and chronic effects of alcohol on iron absorption. Dig Dis Sci 28, 321-327.
44. Chapman RW, Morgan MY, Bell R et al. (1983) Hepatic iron uptake in alcoholic liver disease. Gastroenterology 84, 143-147.
45. Weinberg ED (1986) Iron, infection, and neoplasia. Clin Physiol Biochem 4, 50-60.
46. Bell H, Skinningsrud A, Raknerud N et al. (1994) Serum ferritin and transferrin saturation in patients with chronic alcoholic and nonalcoholic liver diseases. J Intern Med 236, 315-322.
47. Girelli D, Corrocher R, Bisceglia L et al. (1995) Molecular basis for the recently described hereditary hyperferritinemia-cataract syndrome: a mutation in the iron-responsive element of ferritin L-subunit gene (the 'Verona mutation'). Blood 86, 4050-4053.
48. Sullivan LW, Herbert V (1964) Suppression hematopoiesis by ethanol. J Clin Invest 43, 2048-2062.
49. Charlton RW, Jacobs P, Seftel H et al. (1964) Effect of alcohol on iron absorption. Br Med J 5422, 1427-1429.
50. Bacon BR, Tavill AS (1984) Role of the liver in normal iron metabolism. Semin Liver Dis 4, 181-192.
51. Bonkovsky HL, Banner BF, Rothman AL (1997) Iron and chronic viral hepatitis. Hepatology 25, 759-768.
52. Rulyak SJ, Eng SC, Patel K et al. (2005) Relationships between hepatic iron content and virologic response in chronic hepatitis C patients treated with interferon and ribavirin. Am J Gastroenterol 100, 332-337.
53. Fargion S, Mattioli M, Fracanzani AL et al. (2001) Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis. Am J Gastroenterol 96, 2448-2455.
54. Valenti L, Dongiovanni P, Fracanzani AL et al. (2003) Increased susceptibility to nonalcoholic fatty liver disease in heterozygotes for the mutation responsible for hereditary hemochromatosis. Dig Liver Dis 35, 172-178.
55. Kivel RM (1961) Hematologic aspects of acute viral hepatitis. Am J Dig Dis 6, 1017-1031.
56. Firkin FC, Nicholls K, Whelan G (1978) Transient myeloid and erythroid aplasia associated with infectious hepatitis. Br Med J 2, 1534.
57. Pikis A, Kavaliotis J, Manios S (1988) Incidence of aplastic anemia in viral hepatitis in children. Scand J Infect Dis 20, 109-110.
58. Zeldis JB, Dienstag JL, Gale RP (1983) Aplastic anemia and non-A, non-B hepatitis. Am J Med 74, 64-68.
59. Peters M, Trippler M, Lohr H et al. (1995) Posttransfusional, LKM-1-autoantibody-positive hepatitis C virus infection, cryoglobulinemia, and aplastic anemia. Dig Dis Sci 40, 763-773.
60. Hagler L, Pastore RA, Bergin JJ et al. (1975) Aplastic anemia following viral hepatitis: report of two fatal cases and literature review. Medicine (Baltimore) 54, 139-164.
61. Domenech P, Palomeque A, Martinez-Gutierrez A et al. (1986) Severe aplastic anaemia following hepatitis A. Acta Haematol 76, 227-229.
62. Casciato DA, Klein CA, Kaplowitz N et al. (1978) Aplastic anemia associated with type B viral hepatitis. Arch Intern Med 138, 1557-1558.
63. Bannister P, Miloszewski K, Barnard D et al. (1983) Fatal marrow aplasia associated with non-A, non-B hepatitis. Br Med J (Clin Res Ed) 286, 1314-1315.
64. Cargnel A, Vigano P, Davoli C et al. (1983) Sporadic acute non-A non-B hepatitis complicated by aplastic anemia. Am J Gastroenterol 78, 245-247.
65. Brown KE, Tisdale J, Barrett AJ et al. (1997) Hepatitis-associated aplastic anemia. N Engl J Med 336, 1059-1064.
66. Ozsoylu S (1992) Transient hypoplastic anemia of childhood. Am J Hematol 40, 240-241.
67. Ozsoylu S, Coskun T, Minassazi S (1984) High dose intravenous glucocorticoid in the treatment of childhood acquired aplastic anaemia. Scand J Haematol 33, 309-316.
68. Paquette RL, Tebyani N, Frane M et al. (1995) Long-term outcome of aplastic anemia in adults treated with antithymocyte globulin: comparison with bone marrow transplantation. Blood 85, 283-290.
69. Pitcher CS, Williams R (1963) Reduced red cell survival in jaundice and its relation to abnormal glutathione metabolism. Clin Sci 24, 239-252.
70. Fuller SJ, Kumar P, Weltman M et al. (2003) Autoimmune hemolysis associated with primary biliary cirrhosis responding to ursodeoxycholic acid as sole treatment. Am J Hematol 72, 31-33.
71. Mahl MA, von Schonfeld J, Uppenkamp M et al. (1996) [Hemolytic anemia as cause of a marked bilirubin increase in primary biliary cirrhosis.] Dtsch Med Wochenschr 121, 1226-1228.
72. Senzolo M, Cholongitas EC, Patch D et al. (2005) Update on the classification, assessment of prognosis and therapy of Budd-Chiari syndrome. Nature Clin Pract Gastroenterol Hepatol 2, 182-190.
73. Cui W, Zhang Z (2002) [Expression of CD(59) and CD(45) on lymphocytes in paroxysmal nocturnal hemoglobinuria patients.] Zhonghua Xue Ye Xue Za Zhi 23, 77-79.
74. Shichishima T, Terasawa T, Saitoh Y et al. (1993) Diagnosis of paroxysmal nocturnal haemoglobinuria by phenotypic analysis of erythrocytes using two-colour flow cytometry with monoclonal antibodies to DAF and CD59/MACIF. Br J Haematol 85, 378-386.
75. Sanyal AJ, Freedman AM, Purdum PP et al. (1996) The hematologic consequences of transjugular intrahepatic portosystemic shunts. Hepatology 23, 32-39.
76. Cartwright GE, Hodges RE, Gubler CJ et al. (1954) Studies on copper metabolism. XIII. Hepatolenticular degeneration. J Clin Invest 33, 1487-1501.
77. Scheinberg IH, Sternlieb I (1959) The liver in Wilson's disease. Gastroenterology 37, 550-564.
78. McIntyre N, Clink HM, Levi AJ et al. (1967) Hemolytic anemia in Wilson's disease. N Engl J Med 276, 439-444.
79. Lau JY, Lai CL, Wu PC et al. (1990) Wilson's disease: 35 years' experience. Q J Med 75, 597-605.
80. Degenhardt S, Blomhard G, Hefter H et al. (1994) [A hemolytic crisis with liver failure as the first manifestation of Wilson's disease.] Dtsch Med Wochenschr 119, 1421-1426.
81. Gow PJ, Smallwood RA, Angus PW et al. (2000) Diagnosis of Wilson's disease: an experience over three decades. Gut 46, 415-419.
82. Matsumura A, Hiraishi H, Terano A (1999) Plasma exchange for hemolytic crisis in Wilson disease. Ann Intern Med 131, 866.
83. Sen S, Felldin M, Steiner C et al. (2002) Albumin dialysis and Molecular Adsorbents Recirculating System (MARS) for acute Wilson's disease. Liver Transpl 8, 962-967.
84. Smith JA, Lonergan ET, Sterling K (1964) Spur-cell anemia: hemolytic anemia with red cells resembling acanthocytes in alcoholic cirrhosis. N Engl J Med 271, 396-398.
85. Silber R, Amorosi E, Lhowe J et al. (1966) Spur-shaped erythrocytes in Laennec's cirrhosis. N Engl J Med 275, 639-643.
86. Aihara K, Azuma H, Ikeda Y et al. (2001) Successful combination therapy-flunarizine, pentoxifylline, and cholestyramine-for spur cell anemia. Int J Hematol 73, 351-355.
87. Chitale AA, Sterling RK, Post AB et al. (1998) Resolution of spur cell anemia with liver transplantation: a case report and review of the literature. Transplantation 65, 993-995.
88. Thomson A, Kerlin P, Clouston A et al. (1997) Spur cell anaemia resolves after orthotopic liver transplantation (OLT). Aust NZ J Med 27, 198-199.
89. Malik P, Bogetti D, Sileri P et al. (2002) Spur cell anemia in alcoholic cirrhosis: cure by orthotopic liver transplantation and recurrence after liver graft failure. Int Surg 87, 201-204.
90. Zieve L (1958) Jaundice, hyperlipidemia and hemolytic anemia: a heretofore unrecognized syndrome associated with alcoholic fatty liver and cirrhosis. Ann Intern Med 48, 471-496.
91. Zieve L (1966) Hemolytic anaemia in liver disease. Medicine (Baltimore) 45, 497.
92. Veyrac M, Montaron JC, Feneyrou B et al. (1982) [Zieve's syndrome and acute alcoholic hepatitis (author's transl.)]. Nouv Presse Med 11, 2003-2005.
93. Goebel KM (1975) Red cell metabolism in transient haemolytic anaemia associated with Zieve's syndrome. Eur J Clin Invest 5, 83-91.
94. Goebel KM, Goebel FD, Schubotz R et al. (1977) Red cell metabolic and membrane features in haemolytic anaemia of alcoholic liver disease (Zieve's syndrome). Br J Haematol 35, 573-585.
95. Pilcher CR, Underwood RG, Smith HR (1996) Zieve's syndrome a potential surgical pitfall? J R Army Med Corps 142, 84.
96. Pereira SP, O'Donohue J, Wendon J et al. (1997) Maternal and perinatal outcome in severe pregnancy-related liver disease. Hepatology 26, 1258-1262.
97. Knox TA, Olans LB (1996) Liver disease in pregnancy. N Engl J Med 335, 569-576.
98. Sibai BM, Ramadan MK, Usta I et al. (1993) Maternal morbidity and mortality in 442 pregnancies with hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome). Am J Obstet Gynecol 169, 1000-1006.
99. Geary M (1997) The HELLP syndrome. Br J Obstet Gynaecol 104, 887-891.
100. Bis KA, Waxman B (1976) Rupture of the liver associated with pregnancy: a review of the literature and report of 2 cases. Obstet Gynecol Surv 31, 763-773.
101. Shames BD, Fernandez LA, Sollinger HW et al. (2005) Liver transplantation for HELLP syndrome. Liver Transpl 11, 224-228.
102. Burroughs AK (1998) Pregnancy and liver disease. Forum (Genova) 8, 42-58.
103. Burroughs AK, Seong NH, Dojcinov DM et al. (1982) Idiopathic acute fatty liver of pregnancy in 12 patients. Q J Med 51, 481-497.
104. Pursnani KG, Sillin LF, Kaplan DS (1997) Effect of transjugular intrahepatic portosystemic shunt on secondary hypersplenism. Am J Surg 173, 169-173.
105. Gurakar A, Fagiuoli S, Gavaler JS et al. (1994) The use of granulocyte-macrophage colony-stimulating factor to enhance hematologic parameters of patients with cirrhosis and hypersplenism. J Hepatol 21, 582-586.
106. Steinberg HS, Bouffard P, Trepo C et al. (1990) In vitro inhibition of hemopoietic cell line growth by hepatitis B virus. J Virol 64, 2577-2581.
107. Zeldis JB, Boender PJ, Hellings JA et al. (1989) Inhibition of human hemopoiesis by non-A, non-B hepatitis virus. J Med Virol 27, 34-38.
108. Liu YK (1980) Effects of alcohol on granulocytes and lymphocytes. Semin Hematol 17, 130-136.
109. Kusaba N, Kumashiro R, Ogata H et al. (1998) In vitro study of neutrophil apoptosis in liver cirrhosis. Intern Med 37, 11-17.
110. Wirth HP, Heer P, Bertschinger P et al. (1993) [Transient eosinophilia in primary biliary cirrhosis.] Schweiz Med Wochenschr 123, 2278-2283.
111. Yamazaki K, Suzuki K, Nakamura A et al. (1999) Ursodeoxycholic acid inhibits eosinophil degranulation in patients with primary biliary cirrhosis. Hepatology 30, 71-78.
112. Wirth HP, Meyenberger C, Altorfer J et al. (1994) [Eosinophilia in primary biliary cirrhosis: regression under therapy with ursodeoxycholic acid.] Schweiz Med Wochenschr 124, 810-815.
113. Rajkovic IA, Williams R (1985) Mechanisms of abnormalities in host defences against bacterial infection in liver disease. Clin Sci (Lond) 68, 247-253.
114. Rajkovic IA, Williams R (1986) Abnormalities of neutrophil phagocytosis, intracellular killing and metabolic activity in alcoholic cirrhosis and hepatitis. Hepatology 6, 252-262.
115. Fiuza C, Salcedo M, Clemente G et al. (2000) In vivo neutrophil dysfunction in cirrhotic patients with advanced liver disease. J Infect Dis 182, 526-533.
116. DeMeo AN, Andersen BR (1972) Defective chemotaxis associated with a serum inhibitor in cirrhotic patients. N Engl J Med 286, 735-740.
117. Kirsch R, Woodburne VE, Shephard EG et al. (2000) Patients with stable uncomplicated cirrhosis have normal neutrophil function. J Gastroenterol Hepatol 15, 1298-1306.
118. Kumagi T, Akbar F, Horiike N et al. (2001) Increased serum levels of macrophage migration inhibitory factor in alcoholic liver diseases and their expression in liver tissues. Clin Biochem 34, 189-193.
119. Bansi D, Chapman R, Fleming K (1996) Antineutrophil cytoplasmic antibodies in chronic liver diseases: prevalence, titre, specificity and IgG subclass. J Hepatol 24, 581-586.
120. Noguchi H, Hirai K, Aoki Y et al. (1995) Changes in platelet kinetics after a partial splenic arterial embolization in cirrhotic patients with hypersplenism. Hepatology 22, 1682-1688.
121. Yanaga K, Tzakis AG, Shimada M et al. (1989) Reversal of hypersplenism following orthotopic liver transplantation. Ann Surg 210, 180-183.
122. Clavien PA, Camargo CA Jr, Croxford R et al. (1994) Definition and classification of negative outcomes in solid organ transplantation. Application in liver transplantation. Ann Surg 220, 109-120.
123. Blake JC, Sprengers D, Grech P et al. (1990) Bleeding time in patients with hepatic cirrhosis. Br Med J 301, 12-15.
124. Giannini E, Botta F, Borro P et al. (2003) Platelet count/spleen diameter ratio: proposal and validation of a non-invasive parameter to predict the presence of oesophageal varices in patients with liver cirrhosis. Gut 52, 1200-1205.
125. Jabbour N, Zajko A, Orons P et al. (1998) Does transjugular intrahepatic portosystemic shunt (TIPS) resolve thrombocytopenia associated with cirrhosis? Dig Dis Sci 43, 2459-2462.
126. Karasu Z, Gurakar A, Kerwin B et al. (2000) Effect of transjugular intrahepatic portosystemic shunt on thrombocytopenia associated with cirrhosis. Dig Dis Sci 45, 1971-1976.
127. Bolognesi M, Merkel C, Sacerdoti D et al. (2002) Role of spleen enlargement in cirrhosis with portal hypertension. Dig Liver Dis 34, 144-150.
128. N'Kontchou G, Seror O, Bourcier V et al. (2005) Partial splenic embolization in patients with cirrhosis: efficacy, tolerance and long-term outcome in 32 patients. Eur J Gastroenterol Hepatol 17, 179-184.
129. Hidaka H, Kokubu S, Saigenji K et al. (2002) Restoration of thrombopoietin production after partial splenic embolization leads to resolution of thrombocytopenia in liver cirrhosis. Hepatol Res 23, 265.
130. Jelkmann W (2001) The role of the liver in the production of thrombopoietin compared with erythropoietin. Eur J Gastroenterol Hepatol 13, 791-801.
131. Kitano K, Shimodaira S, Ito T et al. (1999) Liver cirrhosis with marked thrombocytopenia and highly elevated serum thrombopoietin levels. Int J Hematol 70, 52-55.
132. Martin TG III, Somberg KA, Meng YG et al. (1997) Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation. Ann Intern Med 127, 285-288.
133. Wang GL, Jiang BH, Rue EA et al. (1995) Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 92, 5510-5514.
134. Nagamine T, Ohtuka T, Takehara K et al. (1996) Thrombocytopenia associated with hepatitis C viral infection. J Hepatol 24, 135-140.
135. Violi F, Ferro D, Basili S et al. (1992) Hyperfibrinolysis increases the risk of gastrointestinal hemorrhage in patients with advanced cirrhosis. Hepatology 15, 672-676.
136. Violi F, Leo R, Basili S et al. (1994) Association between prolonged bleeding time and gastrointestinal hemorrhage in 102 patients with liver cirrhosis: results of a retrospective study. Haematologica 79, 61-65.
137. Kajihara M, Kato S, Okazaki Y et al. (2003) A role of autoantibodymediated platelet destruction in thrombocytopenia in patients with cirrhosis. Hepatology 37, 1267-1276.
138. Feistauer SM, Penner E, Mayr WR et al. (1997) Target platelet antigens of autoantibodies in patients with primary biliary cirrhosis. Hepatology 25, 1343-1345.
139. Escolar G, Cases A, Vinas M et al. (1999) Evaluation of acquired platelet dysfunctions in uremic and cirrhotic patients using the platelet function analyzer (PFA-100): influence of hematocrit elevation. Haematologica 84, 614-619.
140. Owen JS, Hutton RA, Day RC et al. (1981) Platelet lipid composition and platelet aggregation in human liver disease. J Lipid Res 22, 423-430.
141. Laffi G, Marra F, Gresele P et al. (1992) Evidence for a storage pool defect in platelets from cirrhotic patients with defective aggregation. Gastroenterology 103, 641-646.
142. Beer JH, Clerici N, Baillod P et al. (1995) Quantitative and qualitative analysis of platelet GPIb and von Willebrand factor in liver cirrhosis. Thromb Haemost 73, 601-609.
143. Triger DR (1975) Some immunological aspects of liver function. Yale J Biol Med 48, 47-54.
144. Triger DR, Alp MH, Wright R (1972) Bacterial and dietary antibodies in liver disease. Lancet 1, 60-63.
145. Viitala K, Israel Y, Blake JE et al. (1997) Serum IgA, IgG, and IgM antibodies directed against acetaldehyde-derived epitopes: relationship to liver disease severity and alcohol consumption. Hepatology 25, 1418-1424.
146. Seilles E, Rossel M, Vuitton DA et al. (1995) Serum secretory IgA and secretory component in patients with non-cirrhotic alcoholic liver diseases. J Hepatol 22, 278-285.
147. Gonzalez-Quintela A, Alende MR, Gamallo R et al. (2003) Serum immunoglobulins (IgG, IgA, IgM) in chronic hepatitis C. A comparison with non-cirrhotic alcoholic liver disease. Hepatogastroenterology 50, 2121-2126.
148. Schott P, Hartmann H, Ramadori G (2001) Hepatitis C virus-associated mixed cryoglobulinemia. Clinical manifestations, histopathological changes, mechanisms of cryoprecipitation and options of treatment. Histol Histopathol 16, 1275-1285.
149. Pawlotsky JM, Ben Yahia M, Andre C et al. (1994) Immunological disorders in C virus chronic active hepatitis: a prospective case-control study. Hepatology 19, 841-848.
150. Ferri C, Zignego AL, Pileri SA (2002) Cryoglobulins. J Clin Pathol 55, 4-13.
151. Medina J, Garcia-Buey L, Moreno-Otero R (2004) Hepatitis C virusrelated extra-hepatic disease-aetiopathogenesis and management. Aliment Pharmacol Ther 20, 129-141.
152. Myers RP, Regimbeau C, Thevenot T et al. (2002) Interferon for interferon naive patients with chronic hepatitis C. Cochrane Database Syst Rev CD000370.
153. Thevenot T, Regimbeau C, Ratziu V et al. (2001) Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients: 1999 update. J Viral Hepat 8, 48-62.
154. Poynard T, Leroy V, Mathurin P et al. (1996) Treatment of chronic hepatitis C by interferon for longer duration than six months. Dig Dis Sci 41, 99S-102S.
155. Poynard T, Leroy V, Cohard M et al. (1996) Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 24, 778-789.
156. Zuckerman E, Keren D, Slobodin G et al. (2000) Treatment of refractory, symptomatic, hepatitis C virus related mixed cryoglobulinemia with ribavirin and interferon-alpha. J Rheumatol 27, 2172-2178.
157. Sansonno D, De Re V, Lauletta G et al. (2003) Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood 101, 3818-3826.
158. Zaja F, De Vita S, Mazzaro C et al. (2003) Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 101, 3827-3834.
159. Franzin F, Efremov DG, Pozzato G et al. (1995) Clonal B-cell expansions in peripheral blood of HCV-infected patients. Br J Haematol 90, 548-552.
160. Talamini R, Montella M, Crovatto M et al. (2004) Non-Hodgkin's lymphoma and hepatitis C virus: a case-control study from northern and southern Italy. Int J Cancer 110, 380-385.
161. Mazzaro C, Efremov DG, Burrone O et al. (1998) Hepatitis C virus, mixed cryoglobulinaemia and non-Hodgkin's lymphoma. Ital J Gastroenterol Hepatol 30, 428-434.
162. Mazzaro C, Little D, Pozzato G (2002) Regression of splenic lymphoma after treatment of hepatitis C virus infection. N Engl J Med 347, 2168-2170.
163. Kelaidi C, Rollot F, Park S et al. (2004) Response to antiviral treatment in hepatitis C virus-associated marginal zone lymphomas. Leukemia 18, 1711-1716.
164. Levine AM, Shimodaira S, Lai MM (2003) Treatment of HCV-related mantle-cell lymphoma with ribavirin and pegylated interferon alfa. N Engl J Med 349, 2078-2079.
165. Armor JF, Fazili J, Toubia N et al. (2005) Remission of natural-killer cell lymphoma of the liver with anti-hepatitis C therapy. Am J Hematol 78, 212-215.
166. Foxton MR, Knight L, Knisely AS et al. (2005) Liver transplantation for HCV-related cirrhosis in a patient with gastric mucosa-associated lymphoma (MALToma) pretreated with rituximab. Liver Transpl 11, 839-842.
167. Ramos-Casals M, Lopez-Guillermo A, Brito-Zeron P et al. (2004) Treatment of B-cell lymphoma with rituximab in two patients with Sjogren's syndrome associated with hepatitis C virus infection. Lupus 13, 969-971.
168. Lamprecht P, Lerin-Lozano C, Merz H et al. (2003) Rituximab induces remission in refractory HCV associated cryoglobulinaemic vasculitis. Ann Rheum Dis 62, 1230-1233.
169. Schlitt HJ, Schafers S, Deiwick A et al. (1995) Extramedullary erythropoiesis in human liver grafts. Hepatology 21, 689-696.
170. Maheshwari A, Mishra R, Thuluvath PJ (2004) Post-liver-transplant anemia: etiology and management. Liver Transpl 10, 165-173.
171. Triulzi DJ, Shirey RS, Ness PM et al. (1992) Immunohematologic complications of ABO-unmatched liver transplants. Transfusion 32, 829-833.
172. Fung MK, Sheikh H, Eghtesad B et al. (2004) Severe hemolysis resulting from D incompatibility in a case of ABO-identical liver transplant. Transfusion 44, 1635-1639.
173. Cattral MS, Langnas AN, Markin RS et al. (1994) Aplastic anemia after liver transplantation for fulminant liver failure. Hepatology 20, 813-818.
174. Baranski B, Armstrong G, Truman JT et al. (1988) Epstein-Barr virus in the bone marrow of patients with aplastic anemia. Ann Intern Med 109, 695-704.
175. Apperley JF, Dowding C, Hibbin J et al. (1989) The effect of cytomegalovirus on hemopoiesis: in vitro evidence for selective infection of marrow stromal cells. Exp Hematol 17, 38-45.
176. Langnas AN, Markin RS, Cattral MS et al. (1995) Parvovirus B19 as a possible causative agent of fulminant liver failure and associated aplastic anemia. Hepatology 22, 1661-1665.
177. European FK506 Multicentre Liver Study Group (1994) Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. European FK506 Multicentre Liver Study Group. Lancet 344, 423-428.
178. Ndimbie OK, Frezza E, Jordan JA et al. (1996) Parvovirus B19 in anemic liver transplant recipients. Clin Diagn Lab Immunol 3, 756-760.
179. Atassi T, Thuluvath PJ (2003) Risk of colorectal adenoma in liver transplant recipients compared to immunocompetent control population undergoing routine screening colonoscopy. J Clin Gastroenterol 37, 72-73.
180. Cohen AJ, Stegall MD, Rosen CB et al. (2002) Chronic renal dysfunction late after liver transplantation. Liver Transpl 8, 916-921.
181. Pawarode A, Fine DM, Thuluvath PJ (2003) Independent risk factors and natural history of renal dysfunction in liver transplant recipients. Liver Transpl 9, 741-747.
182. Richards EM, Alexander GJ, Calne RY et al. (1997) Thrombocytopenia following liver transplantation is associated with platelet consumption and thrombin generation. Br J Haematol 98, 315-321.
183. Faeh M, Hauser SP, Nydegger UE (2001) Transient thrombopoietin peak after liver transplantation for end-stage liver disease. Br J Haematol 112, 493-498.
184. Goulis J, Chau TN, Jordan S et al. (1999) Thrombopoietin concentrations are low in patients with cirrhosis and thrombocytopenia and are restored after orthotopic liver transplantation. Gut 44, 754-758.
185. Sutedja DS, Wai CT, Teoh KF et al. (2004) Persistent thrombocytopenia in liver transplant patients. Transplant Proc 36, 2331-2333.
186. Duvoux C, Pageaux GP, Vanlemmens C et al. (2002) Risk factors for lymphoproliferative disorders after liver transplantation in adults: an analysis of 480 patients. Transplantation 74, 1103-1109.
187. Pageaux GP, Bonnardet A, Picot MC et al. (1998) Prevalence of monoclonal immunoglobulins after liver transplantation: relationship with posttransplant lymphoproliferative disorders. Transplantation 65, 397-400.
188. Newell KA, Alonso EM, Kelly SM et al. (1997) Association between liver transplantation for Langerhans cell histiocytosis, rejection, and development of posttransplant lymphoproliferative disease in children. J Pediatr 131, 98-104.
189. Newell KA, Alonso EM, Whitington PF et al. (1996) Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression. Transplantation 62, 370-375.
190. Wu L, Rappaport DC, Hanbridge A et al. (2001) Lymphoproliferative disorders after liver transplantation: imaging features. Abdom Imaging 26, 200-206.
191. Aucejo F, Rofaiel G, Miller C (2006) Who is at risk for post-transplant lymphoproliferative disorders (PTLD) after liver transplantation? J Hepatol 44, 19-23.
192. Muti G, Mancini V, Ravelli E et al. (2005) Significance of Epstein-Barr virus (EBV) load and interleukin-10 in post-transplant lymphoproliferative disorders. Leuk Lymphoma 46, 1397-1407.
193. Muti G, Klersy C, Baldanti F et al. (2003) Epstein-Barr virus (EBV) load and interleukin-10 in EBV-positive and EBV-negative posttransplant lymphoproliferative disorders. Br J Haematol 122, 927-933.
194. Capello D, Cerri M, Muti G et al. (2003) Molecular histogenesis of posttransplantation lymphoproliferative disorders. Blood 102, 3775-3785.
195. Leblond V, Davi F, Charlotte F et al. (1998) Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity? J Clin Oncol 16, 2052-2059.
196. Ghobrial IM, Habermann TM, Macon WR et al. (2005) Differences between early and late posttransplant lymphoproliferative disorders in solid organ transplant patients: are they two different diseases? Transplantation 79, 244-247.
197. Tsai DE, Hardy CL, Tomaszewski JE et al. (2001) Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation 71, 1076-1088.
198. Leblond V, Choquet S (2004) Lymphoproliferative disorders after liver transplantation. J Hepatol 40, 728-735.
199. Aull MJ, Buell JF, Trofe J et al. (2004) Experience with 274 cardiac transplant recipients with posttransplant lymphoproliferative disorder: a report from the Israel Penn International Transplant Tumor Registry. Transplantation 78, 1676-1682.
200. Praghakaran K, Wise B, Chen A et al. (1999) Rational management of posttransplant lymphoproliferative disorder in pediatric recipients. J Pediatr Surg 34, 112-115.
201. Jain A, Nalesnik M, Reyes J et al. (2002) Posttransplant lymphoproliferative disorders in liver transplantation: a 20-year experience. Ann Surg 236, 429-436.
202. Benkerrou M, Jais JP, Leblond V et al. (1998) Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: prognostic factors and long-term outcome. Blood 92, 3137-3147.
203. Choquet S, Leblond V, Herbrecht R et al. (2006) Efficacy and safety of rituximab in B-cell post-transplant lymphoproliferative disorders: results of a prospective multicentre phase II study. Blood 107, 3053-3057.